Rhythm Pharmaceuticals, Inc. research snapshot
RYTM AI stock analysis reads Rhythm Pharmaceuticals as a commercial-stage rare-obesity company with a growing IMCIVREE revenue base and a broader MC4R agonist pipeline, but the stock has pulled back from its July high. RYTM closed at $99.25 on July 31, 2026, down 6.14% for the session, and now trades just below the 50-day average near $99.97 and just above the 200-day average near $99.03. Q1 2026 product revenue reached $60.11 million, up 59% year over year, while TTM revenue rose to $217.17 million. The company still reported a $55.64 million quarterly net loss and used $44.19 million in operating cash in Q1 2026. Q2 2026 results are scheduled for August 4, 2026. The central RYTM AI stock forecast question is whether acquired hypothalamic obesity expansion and future pipeline assets can turn revenue growth into durable earnings before commercial spending, clinical risk, and dilution weigh on per-share value. This is informational research, not investment advice.
Current price
$99.25 close on July 31, 2026
Market cap
$6.80 billion calculated from $99.25 x 68.53 million shares; StockAnalysis reported $6.80 billion on August 2, a close match after a 6.14% drop on July 31
AI score
56 / 100
Rating
Commercial rare-obesity platform with growing IMCIVREE revenue, but the July 2026 pullback, negative earnings, customer concentration, and clinical execution risk keep the view cautious
Trend status
Price sits right at the 50-day average near $99.97 and 200-day average near $99.03 after a sharp July decline; short-term momentum weakened and RSI fell from extended to neutral
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Rhythm sells IMCIVREE for rare MC4R pathway diseases and is expanding into acquired hypothalamic obesity. Product revenue is real and growing, but the company remains dependent on one commercial product and a still-developing pipeline. | High |
| Moat | The moat is based on MC4R biology, clinical evidence, regulatory approvals, orphan-disease expertise, patient identification, and intellectual property. Switching costs and network effects are limited, so reimbursement and competing therapies remain important. | Medium |
| Management | David Meeker and the team have moved Rhythm from development into broader commercial execution while keeping a pipeline of next-generation MC4R agonists. The capital allocation test is whether higher selling and clinical spending produces durable revenue and per-share value. | Medium |
| Financial trend | FY2025 total revenue was $189.76 million, up 45.83%, while net loss was $196.54 million and free cash flow was negative $116.63 million. TTM revenue reached $217.17 million with a TTM net loss of about $207.84 million. Q1 2026 product revenue rose 59% year over year to $60.11 million, but net loss was $55.64 million and operating cash use was $44.19 million. | High |
| Valuation | At $99.25, the exact valuation check produced negative TTM P/E of 31.61x, about 55.14x book value, and negative P/FCF of 56.39x. These ratios are not conventional value signals because earnings and free cash flow remain negative. | High |
| Technical trend | The August 2 technical snapshot put the 50-day average at $99.97 and the 200-day average at $99.03, with RSI 40.83 and beta 1.88. The July 31 close of $99.25 sits between the two averages after a pullback from the early July peak near $115.92. | Medium |
| Risk level | Risk is high. Commercial adoption, reimbursement, single-product concentration, clinical readouts, manufacturing, preferred stock, royalty obligations, equity issuance, and a 13.97% short position can all change the thesis. | High |
| AI confidence | The reported financial and regulatory facts are well supported. Confidence is lower for future revenue conversion, pipeline probability, normalized margins, and price scenarios. | Medium |
| Investment certainty | Investment certainty is lower than AI confidence. A good product and growing revenue do not yet prove that Rhythm can fund its commercial and clinical plans without continued losses or dilution. | Low-medium |
RYTM AI stock forecast
The RYTM AI stock forecast is a scenario range, not a point target. StockAnalysis showed a 16-analyst average price target of $138.80, with a low of $105 and a high of $155, and a Strong Buy consensus as of July 27, 2026. Analyst targets are not company guidance and can change quickly. The required financial_rigor.py three-scenario calculation used negative TTM EPS of $3.14 in absolute loss terms and produced mechanically negative reference values, so the practical ranges below focus on product growth, pipeline execution, cash burn, and market multiple risk.
$135 to $155 scenario range
More likely if IMCIVREE uptake in acquired hypothalamic obesity scales in the United States and Europe, Japan approves the pending application, Q2 2026 results show accelerating revenue, PWS Phase 3 planning advances, and bivamelagon or RM-718 adds value without excessive dilution. Wells Fargo holds a $155 target, Canaccord $151, and JPMorgan initiated at $145 on July 27.
$105 to $135 scenario range
More likely if product revenue keeps growing but market access, specialty pharmacy timing, marketing expense, clinical spending, and the negative earnings profile keep the market focused on execution rather than near-term profits. The low analyst target of $105 and the average target of $138.80 frame this zone.
$74.50 to $105 scenario range
More likely if acquired hypothalamic obesity adoption is slow, reimbursement is difficult, Q2 2026 results disappoint, the broader platform loses confidence after the EMANATE miss, pipeline studies disappoint, cash burn accelerates, or Rhythm raises equity while valuation is under pressure. The 52-week low of $74.50 and the low analyst target of $105 define the downside reference.
RYTM AI technical analysis
RYTM AI technical analysis uses the July 31, 2026 close of $99.25 and the StockAnalysis technical snapshot checked August 2, 2026. Price is below the 50-day average near $99.97 and marginally above the 200-day average near $99.03. RSI fell to 40.83 from an extended reading above 70, and the July 31 session dropped 6.14% to $99.25. These are reference levels, not trading instructions.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $99.25 | RYTM closed at $99.25 on July 31, 2026, down 6.14% from $105.74, with a session range of $98.44 to $106.87 and volume near 447,071 shares. |
| Immediate support reference | $98.44 to $99.03 | The July 31 low and the 200-day average define the nearest price-action zone. A break below it would show continued short-term weakness, not a confirmed floor. |
| Intermediate support reference | $95.83 to $96.79 | The June 17 and June 18 lows from the historical price record define the next zone after the July pullback. A break below it would open a path toward the June lows near $85. |
| Near resistance reference | $105.00 to $106.90 | The July 30 and July 31 highs define the nearest recovery zone. A sustained break above it with volume would signal stabilization after the pullback. |
| Upper resistance reference | $108.40 to $110.99 | The July 10 close and July 28 high define the next resistance cluster. A return above this zone would reestablish the early July range before the $115 to $116 highs. |
| Moving averages | 50-day $99.97; 200-day $99.03 | StockAnalysis technical statistics checked August 2, 2026. The averages can change after each trading session and should be refreshed before use. |
| Momentum | RSI 40.83 as of August 2, 2026 | The snapshot describes neutral momentum after the sharp July decline from an extended reading above 70. The indicator should be recalculated from current data before any decision. |
| Volume and volatility | About 447,071 shares on July 31; 20-day average about 610,000; beta 1.88 | The historical price record supplies the July 31 volume and StockAnalysis supplies the 20-day average and beta. Clinical and regulatory news can create gaps larger than ordinary daily volatility. |
| Invalidation reference | Sustained close below $98.44 | A sustained close below the July 31 low and the 200-day average would weaken the longer-term chart structure. A clinical or regulatory announcement can invalidate technical levels immediately. |
RYTM AI trading strategy
The RYTM AI trading strategy is a rules-based research framework, not personalized advice. Use a live chart, the August 4, 2026 Q2 results call, an FDA and clinical-trial calendar, current filings, position sizing, and a plan for overnight gaps because biotech and commercial catalysts can overwhelm ordinary stops.
Wait for price to reclaim and hold the $105.00 to $106.90 resistance reference with volume, then confirm that Q2 2026 revenue, reimbursement progress, Japan review, or a pipeline update supports the move. A breakout without a fundamental catalyst is only a price signal.
A failed breakout followed by a close below $98.44 weakens the short-term setup. A sustained close below $96.79 is a broader trend warning toward the June lows.
If price holds the $98.44 to $99.03 zone near the 200-day average, monitor Q2 2026 revenue, patient start forms, payer access, cash, and share count. The setup tests whether the pullback is technical rather than a change in commercial or clinical probability.
Do not average down only because price reaches a historical level. Reassess after a reimbursement setback, trial failure, safety signal, financing, or a material change in product demand.
Track the August 4, 2026 Q2 results call, Japan PMDA review, acquired hypothalamic obesity launch metrics, IMCIVREE revenue and gross margin, PWS Phase 3 planning, RM-718 data, bivamelagon Phase 3 plans, cash runway, royalty obligations, and common share count.
Lower confidence if revenue growth depends on a small number of customers, operating expenses outrun product revenue, clinical timelines slip, or new equity is issued at an unfavorable price.
Investment research summary
Rhythm sells IMCIVREE, a precision medicine built around MC4R agonism, for rare genetic obesity disorders and acquired hypothalamic obesity. Customers pay for an approved treatment that addresses severe hyperphagia and obesity caused by impaired MC4R pathway signaling. Product revenue reached $194.77 million in 2025 and $60.11 million in Q1 2026, while TTM revenue reached $217.17 million, but the company is still building the commercial organization needed to convert approval into durable operating leverage. The key question is whether rare-disease market access can expand faster than sales, marketing, and clinical costs. Buffett-style question: would this remain a good business if the pipeline stopped expanding?
Rhythm has a developing moat from MC4R pathway expertise, clinical data, regulatory approvals, orphan-disease infrastructure, physician education, patient identification, and intellectual property. The FDA approval in March 2026, the NEJM publication of TRANSCEND results in July 2026, and the positive preliminary PWS data create evidence for a growing rare-disease franchise. There are limited network effects and patients can be sensitive to reimbursement and treatment alternatives. Buffett-style question: which part of the moat would still exist ten years after a better-funded competitor entered?
The failure paths are concentrated. IMCIVREE may grow more slowly than expected in acquired hypothalamic obesity, payers may restrict access, the EMANATE miss may signal limits to broader genetic indications, or future PWS, RM-718, and bivamelagon studies may fail. The stock fell from about $115 in early July to about $99 by July 31 despite the NEJM publication, showing that positive evidence does not automatically reprice the shares. Even successful revenue growth may not create per-share value if selling costs, royalty obligations, preferred stock, or equity issuance consume the economics. Munger-style question: what fact would make the current valuation look obviously too optimistic?
David Meeker is Chairman, President, and CEO. Management has invested heavily in commercialization, expanded international infrastructure, and continued clinical work while using equity and preferred financing to extend the runway. The 2025 follow-on offering issued 2.367647 million common shares, and a February 2026 ATM agreement permits up to $200 million of additional sales. The company reported cash, cash equivalents, and short-term investments of $340.6 million at March 31, 2026 and said that resources should fund planned operations for at least 24 months. The capital allocation test is whether these investments create profitable product revenue before dilution becomes a larger part of the return. Management question: if the CEO left, would the commercial and clinical system still compound?
Rare obesity medicine sits inside a long-term shift toward genetically defined, mechanism-specific treatment rather than one broad obesity category. MC4R agonism addresses a narrower population than mainstream GLP-1 markets, but severe hyperphagia and hypothalamic obesity have limited treatment options. Rhythm is positioned at the approved-product and specialist-care layer, with the opportunity to expand through Europe, Japan, PWS, acquired hypothalamic obesity, and next-generation agents. The ceiling is constrained by rare-disease prevalence, payer budgets, manufacturing, and competitors. Li Lu-style question: in twenty years, will MC4R agonism be a durable rare-disease standard or a short-lived niche?
At $99.25, the calculated equity value is about $6.80 billion against negative TTM earnings and negative free cash flow. The exact check produced negative TTM P/E of 31.61x, about 55.14x book value, and negative P/FCF of 56.39x. The price therefore depends on future product growth, acquired hypothalamic obesity conversion, pipeline probability, and operating leverage rather than current earnings. The margin of safety is limited unless the reader gives high probability to sustained revenue growth and eventual profitability. Buffett-style question: if the market closed for five years, would the current price be justified by the cash flows the business can reasonably produce?
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| RYTM closing price and session range | $99.25 close on July 31, 2026; down 6.14% on the day; range $98.44 to $106.87; volume about 447,071 | StockAnalysis historical data, S&P Global Market Intelligence | August 3, 2026 |
| Market cap and shares | $6.80B calculated from $99.25 x 68.53M shares; 68.53M shares outstanding as of August 2026, up 7.27% year over year | StockAnalysis statistics and financial_rigor.py market-cap check | August 3, 2026 |
| FY2025 financial results | $189.76M total revenue; $196.54M net loss; $116.63M negative free cash flow | SEC FY2025 Form 10-K and StockAnalysis financials and cash flow | August 3, 2026 |
| Five-year operating trend | Revenue rose from $3.15M in 2021 to $189.76M in 2025; net income remained negative in each year shown; TTM revenue reached $217.17M | StockAnalysis standardized income statement | August 3, 2026 |
| Q1 2026 operating results | $60.11M product revenue; $55.64M net loss; $44.19M cash used in operating activities | SEC Q1 2026 Form 10-Q and Rhythm Q1 2026 business update | August 3, 2026 |
| Cash and obligations | $340.6M cash, cash equivalents, and short-term investments; $204.7M total liabilities at March 31, 2026 | SEC Q1 2026 Form 10-Q and Rhythm Q1 2026 release | August 3, 2026 |
| Commercial and regulatory catalysts | IMCIVREE FDA approval for acquired hypothalamic obesity on March 19, 2026; European Commission authorization on May 1; Japan PMDA decision expected in the second half of 2026; Q2 2026 results scheduled for August 4, 2026 | Rhythm Q2 2026 reporting-date release and regulatory releases | August 3, 2026 |
| Phase 3 TRANSCEND evidence | NEJM publication on July 8, 2026: placebo-adjusted BMI difference of 19.8%; primary analysis showed mean BMI change of 16.5% reduction for setmelanotide versus 3.3% increase for placebo at 52 weeks (p<0.0001) | Rhythm NEJM publication release | August 3, 2026 |
| Pipeline evidence | Phase 2 PWS data in 17 treated patients showed a mean BMI reduction of 3.06% at Month 6 at ENDO 2026; the trial remains ongoing | Rhythm ENDO 2026 data release | August 3, 2026 |
| Dilution and financing | 2.367647M common shares issued in the July 2025 follow-on offering; February 2026 ATM permits up to $200M of common stock sales; shares up 7.27% year over year | SEC Q1 2026 Form 10-Q and StockAnalysis statistics | August 3, 2026 |
| Technical snapshot | 50-day average $99.97; 200-day average $99.03; RSI 40.83; beta 1.88; 20-day average volume about 609,815 | StockAnalysis statistics, checked August 2, 2026 | August 3, 2026 |
| Analyst price reference | $138.80 average target from 16 analysts with a Strong Buy consensus; low $105, high $155; JPMorgan initiated at $145 on July 27, 2026; not company guidance and not a guaranteed outcome | StockAnalysis forecast and ratings data | August 3, 2026 |
| Short interest | 9.57M shares sold short, about 13.97% of shares outstanding and 17.20% of float, with a short ratio near 9.02 days to cover | StockAnalysis short selling statistics | August 3, 2026 |
| Valuation calculation record | Negative TTM P/E 31.61x; P/B 55.14x; negative P/FCF 56.39x; PS 31.31x; three-scenario negative reference values because TTM EPS is negative | Local financial_rigor.py verify-valuation and three-scenario commands | August 3, 2026 |
This RYTM AI stock analysis page is an informational research tool, not investment advice, a recommendation, or a promise of returns. Forecast ranges are scenario outputs based on available data and assumptions that can be wrong. Verify current prices, filings, clinical and regulatory updates, Q2 2026 results, reimbursement, technical levels, tax rules, and personal suitability before making any financial decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
